Targeting Androgen Receptor in Breast Cancer: Enzalutamide as a Novel Breast Cancer Therapeutic
Abstract
In breast cancer the androgen receptor (AR) is more widely expressed than estrogen receptor alpha (ER) orthe progesterone receptor (PR), suggesting a potential role for AR in BC. To explore the function of AR in models of the three main subtypes of breast cancer (ER positive, ER negative and Her2+), we are using a new-generation AR inhibitor,enzalutamide (Enza), which impairs nuclear localization of AR. Our research seeks to determine whether Enza will be effective in breast cancer and utilize preclinical models to determine if and how it should be combined with standard treatments with the primary objective being to guide future clinical trials. In Dec 2015 Drs. Elias and Richer, demonstrate synergy between Enza and Tamoxifen or Fulvestrant in vitro and results of a Phase 1 study (NCT01597193) on pharmacokinetics and safety of Enza plus Fulvestrant in women with advanced ER+ disease. Regarding TNBC, we reported that ARis anti-apoptotic and facilitates anchorage independent growth and Enza decreased tumor viability in vivo. Here we report on the two trials in ER+ breast cancer one completed enrollment (the trial for women with persistent metastatic ER+ breast cancer and the other (a neoadjuvant trial) with fulvestrant alone compared to fulvestrant plus enzalutamide just finishing up.
Document Details
- Document Type
- Technical Report
- Publication Date
- Sep 01, 2022
- Accession Number
- AD1192028
Entities
People
- Jennifer K Richer
Organizations
- University of Colorado Boulder